Gerresheimer (ETR:GXI) has been assigned a €81.00 ($94.19) price target by analysts at Berenberg Bank in a research report issued on Thursday. The brokerage presently has a “buy” rating on the stock. Berenberg Bank’s target price would indicate a potential upside of 22.54% from the company’s previous close.
A number of other research analysts have also weighed in on GXI. Goldman Sachs Group set a €70.00 ($81.40) target price on Gerresheimer and gave the company a “neutral” rating in a report on Monday, June 18th. Deutsche Bank set a €77.00 ($89.53) target price on Gerresheimer and gave the company a “buy” rating in a report on Tuesday, June 19th. Commerzbank set a €68.00 ($79.07) target price on Gerresheimer and gave the company a “neutral” rating in a report on Thursday, June 21st. Hauck & Aufhaeuser set a €52.50 ($61.05) target price on Gerresheimer and gave the company a “sell” rating in a report on Monday, July 2nd. Finally, JPMorgan Chase & Co. set a €79.40 ($92.33) price target on Gerresheimer and gave the stock a “neutral” rating in a report on Friday, July 6th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of €71.92 ($83.62).
GXI stock opened at €66.10 ($76.86) on Thursday. Gerresheimer has a twelve month low of €59.97 ($69.73) and a twelve month high of €78.25 ($90.99).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.